Xenetic Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	-3.96	-4.13	-6.55	-5.65	-10.89	Upgrade
Depreciation & Amortization	-	-	0.03	0.04	0.03	Upgrade
Asset Writedown & Restructuring Costs	-	-	1.79	-	9.24	Upgrade
Stock-Based Compensation	0.17	0.28	0.51	0.41	0.47	Upgrade
Other Operating Activities	-	-	-	-	-3.06	Upgrade
Change in Accounts Payable	0.08	-0.26	-0.35	0.46	-0.38	Upgrade
Change in Other Net Operating Assets	0.89	0	-0.08	0	0.33	Upgrade
Operating Cash Flow	-2.82	-4.11	-4.65	-4.74	-4.27	Upgrade
Sale (Purchase) of Intangibles	-	-	-0.5	-	-	Upgrade
Investing Cash Flow	-	-	-0.5	-	-	Upgrade
Issuance of Common Stock	-	-	-	11.45	5.43	Upgrade
Financing Cash Flow	-	-	-	11.45	5.43	Upgrade
Net Cash Flow	-2.82	-4.11	-5.15	6.72	1.16	Upgrade
Free Cash Flow	-2.82	-4.11	-4.65	-4.74	-4.27	Upgrade
Free Cash Flow Margin	-112.69%	-161.98%	-272.23%	-408.21%	-976.60%	Upgrade
Free Cash Flow Per Share	-1.83	-2.69	-3.27	-4.61	-6.67	Upgrade
Levered Free Cash Flow	-2.19	-2.85	-4.56	-2.29	-3.07	Upgrade
Unlevered Free Cash Flow	-2.19	-2.85	-4.56	-2.29	-3.07	Upgrade
Change in Net Working Capital	-0.27	0.31	0.4	-0.86	0.63	Upgrade

Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q